Drug intelligence / Profile preview

ANN-003

Development stage: Preclinical
Lead developer: Abeona Therapeutics
Modality: Gene Therapies

Overview

ANN-003 is a gene therapy candidate developed for the treatment of Friedreich's ataxia. It was initially part of Annapurna Therapeutics SAS's pipeline, having been licensed from Weill Cornell Medicine. Following the acquisition of Annapurna Therapeutics by Avalanche Biotechnologies (which was subsequently renamed Adverum Biotechnologies), ANN-003 became part of the combined company's gene therapy portfolio, focusing on rare genetic diseases.

Beyond the preview

Go deeper on ANN-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANN-003.

Explore the full profile